SINGAPORE (Nov 23): OCBC has upgraded its call on Raffles Medical Group to “buy” with an unchanged target price of $4.59, following the stock’s recent correction caused by lower-than-expected growth in 3Q earnings.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply